RTOG-1114

Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine with and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma

Principal Investigator

Antonio Omuro

Status

Disease Site

Brain [BN] Other

Phase

II

Developmental Therapeutics

No

Primary Objective

To determine median progression-free survival (PFS) in both arms on an intent-to-treat basis. PFS will be defined as the interval from randomization to progression or death, whichever occurs first.

Data Collection Notice:

Data for this trial is being collected via the NRG/RTOG Data Center.

Patient Population

B-cell non-Hodgkin’s lymphoma involving the brain, as demonstrated by contrasted MRI and histologic confirmation by one of the following within 6 weeks prior to registration:

 
• A positive CSF cytology for lymphoma or a monoclonal lymphocyte population as defined by cell surface markers

 

• A biopsy of the vitreous or uvea demonstrating non-Hodgkin’s lymphoma

 

• Brain biopsy

 

Target Accrual

89